Certis Oncology Solutions is a life science technology company with a mission to realize the promise of precision oncology. Our product is Oncology Intelligence™— highly predictive therapeutic response data derived from proprietary biological models of cancer. We apply these models to machine learning and AI-enhanced predictive algorithms, the development of the next generation of targeted cancer therapeutics, and functional precision medicine.

Established in 2016, Certis began its journey in functional precision oncology, helping cancer patients and their oncologists through YourPDX™ testing.

ACCELERATING THE DEVELOPMENT OF NEW CANCER THERAPIES
Certis partners with therapeutic developers to help close the problematic translational gap between preclinical studies and clinical trials. Through clinically relevant, well-characterized and annotated cancer models, advanced imaging technology, including x-ray irradiation with image-guided radiation therapy, and thoughtfully designed custom studies, our proprietary platform can bring greater certainty to go/no-go drug development decisions.

We are committed to providing translationally relevant preclinical models to drug developers for efficient and effective transition into the clinic.  Learn more about our preclinical oncology services.

Certis Oncology Solutions, Inc.

Certis Oncology announces closing of $10 million Series C fundraising round and names John R. Tozzi as new board chairman. Read the full press release now: https://hubs.la/Q02gPk9h0. #SeriesC #Fundraising #NewBoardMember #CancerResearch #LifesSciences #FightCancerTogether

Did you miss our recent talk on animal welfare in the preclinical CRO space? Register now to watch the full webinar recording hosted by Inside Scientific: https://hubs.la/Q02jc1Jc0. #CancerResearch #3Rs #AnimalWelfare #MouseModels #CancerModels #TranslationalResearch #FightCancer #CertaintySavesLives 

Stop by a Live Certis Poster Session Today at the 8th Annual Tumor Models San Francisco Summit! 
The Certis Team will present “In Vivo Tumor Implantation Site Exhibits Differential Immune Response in Solid Tumors” on Wednesday, January 31, at 4:50pm (PST). This upcoming poster presentation demonstrates differences in the tumor microenvironment, overall immune response, and the pharmacological outcome, between subcutaneous and orthotopic humanized PDX models using peripheral blood mononuclear cells. This sample figure shows a pathway enrichment analysis of top differentially expressed genes between subcutaneous and orthotopic tissue of PDX models that may functionally contribute to differences in therapy response.  

Find Your Model Match at the Certis Exhibitor Booth
Talk to us about your unique cancer model needs at the upcoming Tumor Models SF Summit! Finding the right preclinical models to evaluate efficacy and understand the complex mechanisms of action induced by your targeting compound(s) can be challenging. A strategic translational approach – combining the predictive power of artificial intelligence with advanced PDX and PDX-derived models – can accelerate your preclinical program. The cancer model database includes 56 unique PDX models and companion PDX-derived 3D cell cultures with the most common RAS mutations in cancer, including lung, colorectal, and pancreatic. Download the data pack now: https://hubs.la/Q02gjHBm0. #TMSF24 #TumorModels #WestCoastBioPharma #TranslationGap #CancerResearch #FightCancer #RareCancers #MetastaticCancers #CertaintySavesLives #CancerArtificialIntelligence #AI #IO #DrugDevelopment #DrugDiscovery  

Nanoligent is a competitor of Certis Oncology Solutions specializing in advanced molecular and immune profiling services for oncology. They offer comprehensive genomic profiling to guide treatment decisions.

Nanoligent

Rincon Bio is a competitor of Certis Oncology Solutions, providing advanced molecular and immune profiling services for oncology. They focus on comprehensive genomic profiling to support precision medicine in cancer treatment.

Rincon Bio

Xentech is a competitor of Certis Oncology Solutions, specializing in advanced molecular and immune profiling services for oncology. They aim to provide comprehensive genomic profiling to assist in treatment decisions for cancer patients.

Xentech

Certis Oncology Solutions is a company that specializes in providing advanced molecular and immune profiling services for oncology. Their services are aimed at supporting precision medicine in cancer treatment, offering comprehensive genomic profiling to help guide treatment decisions.

Certis Oncology Solutions

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	May 12, 2024 12:51 PM	312928ad
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 12, 2024 6:40 PM	9b7790cd
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 12, 2024 12:51 PM	5c55eea4
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 12, 2024 12:51 PM	2168adee
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:CERTISONCOLOGY

Certis Oncology Solutions